INmune Bio Inc美股招股说明书(2025-12-19版)

PROSPECTUS SUPPLEMENT(To Prospectus Dated August 7, 2024) Up to $65,000,000 of Shares of Common Stock INMUNE BIO INC. We have entered into a sales agreement with A.G.P./Alliance Global Partners (“A.G.P.” or “the Sales Agent”), dated December 19,2025 (the “Sales Agreement”), relating to the sale of shares of our common stock, $0.001 par value per share (the “common stock”),offered by this prospectus supplement and the accompanying base prospectus. As described below, we are offering under this Our common stock is listed on the Nasdaq Capital Market (“Nasdaq” or the “Nasdaq Capital Market”) under the symbol “INMB.” OnDecember 18, 2025, the last reported sale price of our common stock on Nasdaq was $1.82 per share. Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be an “at the market offering” asdefined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). A.G.P. is not required tosell any specific number or dollar amount of our common stock, but will act as a Sales Agent using commercially reasonable effortsconsistent with its normal trading and sales practices, on mutually agreed terms between A.G.P. and us. The shares of our common The compensation to A.G.P. for sales of shares of our common stock sold pursuant to the Sales Agreement will be equal to 3.0% of thegross proceeds from each such sale. In connection with the sale of shares of common stock on our behalf, A.G.P. will be deemed to bean “underwriter” within the meaning of the Securities Act, and the compensation of A.G.P. will be deemed to be underwriting Investing in our common stock involves significant risks. Please read the information contained in or incorporated byreference under the heading “Risk Factors” beginning on page S-4 of this prospectus supplement, and under similar headings Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any A.G.P. The date of this prospectus supplement is December 19, 2025. TABLE OF CONTENTS Prospectus Supplement Prospectus ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying base prospectus are part of a shelf registration statement on Form S-3 (File No.333-279036) that we have filed with the Securities and Exchange Commission (the “SEC”) on May 1, 2024, as amended on August 2,2024, and was declared effective by the SEC on August 7, 2024, utilizing a “shelf” registration process. Under the shelf registrationprocess, we may offer securities having an aggregate offering price of up to $250,000,000 under the accompanying base prospectus.This prospectus supplement may add to, update or change information in the accompanying base prospectus and the documentsincorporated by reference into this prospectus supplement or the accompanying base prospectus. Before buying any of the shares of This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and alsoadds to and updates information contained in the accompanying base prospectus and the documents incorporated by reference hereinor therein. The second part, the accompanying base prospectus, provides more general information. Generally, when we refer to thisprospectus supplement, we are referring to both parts of this document combined. To the extent there is a conflict between theinformation contained in this prospectus supplement, on the one hand, and the information contained in any document incorporated byreference into this prospectus supplement that was filed with the SEC before the date of this prospectus supplement, on the other hand, We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to anydocument that is incorporated by reference herein or in the accompanying base prospectus were made solely for the benefit of theparties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanyingbase prospectus and any free writing prospectuses we may provide to you in connection with this offering. We have not, and A.G.P.has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistentinformation, you should not rely on it. We are not, and A.G.P. is not, making an offer to sell or seeking an offer to buy shares of ourcommon stock under this prospectus supplement and the accompanying base prospectus in any jurisdiction where the offer or sale is Furthermore, you should not consider this prospectus supplement and the accompanying base prospectus to be an offer